Trial record 1 of 1 for:    NCT01256398
Previous Study | Return to List | Next Study

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by National Cancer Institute (NCI)
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01256398
First received: December 7, 2010
Last updated: July 9, 2014
Last verified: July 2014
  Purpose

This phase II clinical trial is studying how well dasatinib followed by stem cell transplant works in treating older patients with newly diagnosed acute lymphoblastic leukemia. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving more than one drug (combination chemotherapy) and giving dasatinib together with chemotherapy may kill more cancer cells.


Condition Intervention Phase
Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia
Untreated Adult Acute Lymphoblastic Leukemia
Biological: alemtuzumab
Drug: dasatinib
Drug: daunorubicin hydrochloride
Drug: fludarabine phosphate
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: autologous hematopoietic stem cell transplantation
Procedure: in vitro-treated peripheral blood stem cell transplantation
Drug: dexamethasone
Drug: cyclophosphamide
Biological: filgrastim
Biological: pegfilgrastim
Drug: methotrexate
Drug: leucovorin calcium
Drug: melphalan
Drug: tacrolimus
Drug: etoposide phosphate
Drug: cytarabine
Drug: mercaptopurine
Drug: vincristine sulfate
Other: pharmacological study
Other: laboratory biomarker analysis
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A PHASE II STUDY OF DASATINIB (SPRYCEL®) (NSC #732517) AS PRIMARY THERAPY FOLLOWED BY TRANSPLANTATION FOR ADULTS ≥ 18 YEARS WITH NEWLY DIAGNOSED PH+ ACUTE LYMPHOBLASTIC LEUKEMIA BY CALGB, ECOG AND SWOG

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Disease-free survival (DFS) [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05.


Secondary Outcome Measures:
  • Probability of being BCR-ABL negative in the bone marrow and peripheral blood at the completion of the CNS prophylaxis course (restricted to those patients achieving a complete response [CR]) [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    Proportions will be estimated based on the combined and individual cohorts.

  • Feasibility of maintenance therapy in this patient population (restricted to those patients achieving a CR) [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    Proportions will be estimated based on the combined and individual cohorts.

  • Overall survival [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05.

  • DFS [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05.

  • Response [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 66
Study Start Date: December 2010
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (chemotherapy, transplant)
See Detailed Description
Biological: alemtuzumab
Given IV
Other Names:
  • anti-CD52 monoclonal antibody
  • Campath-1H
  • MoAb CD52
  • Monoclonal Antibody Campath-1H
  • Monoclonal Antibody CD52
Drug: dasatinib
Given PO
Other Names:
  • BMS-354825
  • Sprycel
Drug: daunorubicin hydrochloride
Given IV
Other Names:
  • Cerubidin
  • Cerubidine
  • daunomycin hydrochloride
  • daunorubicin
  • RP-13057
Drug: fludarabine phosphate
Given IV
Other Names:
  • 2-F-ara-AMP
  • Beneflur
  • Fludara
Procedure: allogeneic hematopoietic stem cell transplantation
Undergo peripheral blood allogeneic HCT
Procedure: autologous hematopoietic stem cell transplantation
Undergo peripheral blood autologous HCT
Procedure: in vitro-treated peripheral blood stem cell transplantation
Undergo peripheral blood autologous or allogeneic HCT
Other Names:
  • in vitro-treated PBPC transplantation
  • in vitro-treated PBSC
  • in vitro-treated peripheral blood progenitor cell transplantation
  • PBPC transplantation, in vitro-treated
  • peripheral blood progenitor cell transplantation, in vitro-treated
Drug: dexamethasone
Given PO or IV
Other Names:
  • Aeroseb-Dex
  • Decaderm
  • Decadron
  • DM
  • DXM
Drug: cyclophosphamide
Given IV
Other Names:
  • CPM
  • CTX
  • Cytoxan
  • Endoxan
  • Endoxana
Biological: filgrastim
Given SC
Other Names:
  • G-CSF
  • Neupogen
Biological: pegfilgrastim
Given SC
Other Names:
  • Filgrastim SD-01
  • GCSF-SD01
  • Neulasta
  • SD-01 sustained duration G-CSF
Drug: methotrexate
Given IT, IV, or PO
Other Names:
  • amethopterin
  • Folex
  • methylaminopterin
  • Mexate
  • MTX
Drug: leucovorin calcium
Given IV or PO
Other Names:
  • CF
  • CFR
  • LV
Drug: melphalan
Given IV
Other Names:
  • Alkeran
  • CB-3025
  • L-PAM
  • L-phenylalanine mustard
  • L-Sarcolysin
Drug: tacrolimus
Given IV or PO
Other Names:
  • FK 506
  • Prograf
Drug: etoposide phosphate
Given IV
Other Names:
  • ETOP
  • Etopophos
Drug: cytarabine
Given IV
Other Names:
  • ARA-C
  • arabinofuranosylcytosine
  • arabinosylcytosine
  • Cytosar-U
  • cytosine arabinoside
Drug: mercaptopurine
Given PO
Other Names:
  • 6-mercaptopurine
  • 6-MP
  • Leukerin
  • MP
Drug: vincristine sulfate
Given IV
Other Names:
  • leurocristine sulfate
  • VCR
  • Vincasar PFS
Other: pharmacological study
Correlative studies
Other Name: pharmacological studies
Other: laboratory biomarker analysis
Correlative studies

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Unequivocal histologic diagnosis of ALL
  • Detection of the t(9;22)(q34;q11) or 3-way variant by metaphase cytogenetics or BCR-ABL positive status by molecular analysis (Q-PCR or fluorescent in situ hybridization [FISH]) in a Cruise Lines International Association (CLIA)-approved laboratory
  • No prior therapy except up to one week of corticosteroids and/or hydroxyurea to enable time for the detection of t(9;22)(q34;q11) or BCR/ABL
  • Non-pregnant and non-nursing; treatment under this protocol would expose an unborn child to significant risks; women and men of reproductive potential should agree to use an effective means of birth control and contraception should continue for three months after the last dose of dasatinib to allow complete clearance of drug and its principal metabolites from the body; in women of childbearing potential, a pregnancy test will be required at study entry
  • Left ventricular ejection fraction >= lower limit of institutional normal
  • No myocardial infarction within 6 months
  • No ventricular tachyarrhythmia within 6 months
  • No major conduction abnormality (unless a cardiac pacemaker is present)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01256398

  Hide Study Locations
Locations
United States, California
Stanford University Hospitals and Clinics Active, not recruiting
Stanford, California, United States, 94305
United States, Colorado
The Medical Center of Aurora Recruiting
Aurora, Colorado, United States, 80012
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Boulder Community Hospital Recruiting
Boulder, Colorado, United States, 80301
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Boulder Recruiting
Boulder, Colorado, United States, 80304
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Penrose Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Penrose-Saint Francis Healthcare Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Presbyterian - Saint Lukes Medical Center - Health One Recruiting
Denver, Colorado, United States, 80218
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Exempla Saint Joseph Hospital Recruiting
Denver, Colorado, United States, 80218
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Colorado Cancer Research Program CCOP Recruiting
Denver, Colorado, United States, 80224-2522
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Midtown Recruiting
Denver, Colorado, United States, 80218
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Porter Adventist Hospital Recruiting
Denver, Colorado, United States, 80210
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Colorado Blood Cancer Institute Recruiting
Denver, Colorado, United States, 80907
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Rose Recruiting
Denver, Colorado, United States, 80220
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rose Medical Center Recruiting
Denver, Colorado, United States, 80220
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Mercy Medical Center Recruiting
Durango, Colorado, United States, 81301
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Swedish Medical Center Recruiting
Englewood, Colorado, United States, 80113
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Comprehensive Cancer Care and Research Institute of Colorado LLC Recruiting
Englewood, Colorado, United States, 80113
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Mountain Blue Cancer Care Center Recruiting
Golden, Colorado, United States, 80401
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
North Colorado Medical Center Recruiting
Greeley, Colorado, United States, 80631
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Breast Cancer Care Consultants Recruiting
Greenwood Village, Colorado, United States, 80111
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Lakewood Recruiting
Lakewood, Colorado, United States, 80228
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Saint Anthony Hospital Recruiting
Lakewood, Colorado, United States, 80228
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Littleton Adventist Hospital Recruiting
Littleton, Colorado, United States, 80122
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Sky Ridge Medical Center Recruiting
Lone Tree, Colorado, United States, 80124
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Sky Ridge Recruiting
Lone Tree, Colorado, United States, 80124
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Longmont United Hospital Recruiting
Longmont, Colorado, United States, 80501
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Longmont Recruiting
Longmont, Colorado, United States, 80501
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
McKee Medical Center Recruiting
Loveland, Colorado, United States, 80539
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Parker Adventist Hospital Recruiting
Parker, Colorado, United States, 80138
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers-Parker Recruiting
Parker, Colorado, United States, 80138
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Rocky Mountain Cancer Centers - Pueblo Recruiting
Pueblo, Colorado, United States, 81008
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Saint Mary Corwin Medical Center Recruiting
Pueblo, Colorado, United States, 81004
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Exempla Lutheran Medical Center Recruiting
Wheat Ridge, Colorado, United States, 80033
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
United States, Delaware
Beebe Medical Center Recruiting
Lewes, Delaware, United States, 19958
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
Delaware Clinical and Laboratory Physicians PA Recruiting
Newark, Delaware, United States, 19713
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
Christiana Care Health System-Christiana Hospital Recruiting
Newark, Delaware, United States, 19718
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
Christiana Gynecologic Oncology LLC Recruiting
Newark, Delaware, United States, 19713
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
Helen F Graham Cancer Center Recruiting
Newark, Delaware, United States, 19713
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
Regional Hematology and Oncology PA Recruiting
Newark, Delaware, United States, 19713
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
Medical Oncology Hematology Consultants PA Recruiting
Newark, Delaware, United States, 19713
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
Beebe Health Campus Recruiting
Rehoboth Beach, Delaware, United States, 19971
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
Nanticoke Memorial Hospital Recruiting
Seaford, Delaware, United States, 19973
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
Christiana Care Health System-Wilmington Hospital Recruiting
Wilmington, Delaware, United States, 19801
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
United States, Florida
Florida Hospital Recruiting
Orlando, Florida, United States, 32803
Contact: Lee M. Zehngebot    407-303-5623      
Principal Investigator: Lee M. Zehngebot         
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Contact: Wendy Stock    773-834-7424      
Principal Investigator: Wendy Stock         
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Olga Frankfurt    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Olga Frankfurt         
Hematology and Oncology Associates Terminated
Chicago, Illinois, United States, 60611
University of Illinois Recruiting
Chicago, Illinois, United States, 60612
Contact: John G. Quigley    312-355-3046      
Principal Investigator: John G. Quigley         
Cancer and Leukemia Group B Recruiting
Chicago, Illinois, United States, 60606
Contact: Meir Wetzler    716-845-8447    meir.wetzler@roswellpark.org   
Principal Investigator: Meir Wetzler         
Presence Saint Mary's Hospital Active, not recruiting
Kankakee, Illinois, United States, 60901
North Shore Hematology Oncology Active, not recruiting
Libertyville, Illinois, United States, 60048
Illinois Cancer Specialists-Niles Active, not recruiting
Niles, Illinois, United States, 60714
Hematology Oncology Associates of Illinois - Skokie Active, not recruiting
Skokie, Illinois, United States, 60076
United States, Indiana
Fort Wayne Medical Oncology and Hematology Inc-Parkview Recruiting
Fort Wayne, Indiana, United States, 46845
Contact: Sreenivasa R. Nattam    260-484-8830    ledgar@fwmoh.com   
Principal Investigator: Sreenivasa R. Nattam         
United States, Kansas
Cancer Center of Kansas - Chanute Recruiting
Chanute, Kansas, United States, 66720
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Dodge City Recruiting
Dodge City, Kansas, United States, 67801
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - El Dorado Recruiting
El Dorado, Kansas, United States, 67042
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Fort Scott Recruiting
Fort Scott, Kansas, United States, 66701
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Independence Recruiting
Independence, Kansas, United States, 67301
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
University of Kansas Medical Center Recruiting
Kansas City, Kansas, United States, 66160
Contact: Tara L. Lin    504-568-3410    aconne1@lsuhsc.edu   
Principal Investigator: Tara L. Lin         
Cancer Center of Kansas-Kingman Recruiting
Kingman, Kansas, United States, 67068
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Lawrence Memorial Hospital Recruiting
Lawrence, Kansas, United States, 66044
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Liberal Recruiting
Liberal, Kansas, United States, 67901
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Manhattan Recruiting
Manhattan, Kansas, United States, 66502
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - McPherson Recruiting
McPherson, Kansas, United States, 67460
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Newton Recruiting
Newton, Kansas, United States, 67114
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Parsons Recruiting
Parsons, Kansas, United States, 67357
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Pratt Recruiting
Pratt, Kansas, United States, 67124
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Salina Recruiting
Salina, Kansas, United States, 67401
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Wellington Recruiting
Wellington, Kansas, United States, 67152
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Main Office Recruiting
Wichita, Kansas, United States, 67214
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas-Wichita Medical Arts Tower Recruiting
Wichita, Kansas, United States, 67208
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Associates In Womens Health Recruiting
Wichita, Kansas, United States, 67208
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Via Christi Regional Medical Center Recruiting
Wichita, Kansas, United States, 67214
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Wesley Medical Center Recruiting
Wichita, Kansas, United States, 67214
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Wichita CCOP Recruiting
Wichita, Kansas, United States, 67214
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
Cancer Center of Kansas - Winfield Recruiting
Winfield, Kansas, United States, 67156
Contact: Shaker R. Dakhil    316-262-4467      
Principal Investigator: Shaker R. Dakhil         
United States, Maine
Harold Alfond Center for Cancer Care Recruiting
Augusta, Maine, United States, 04330
Contact: Thomas H. Openshaw    207-973-4274      
Principal Investigator: Thomas H. Openshaw         
Eastern Maine Medical Center Recruiting
Bangor, Maine, United States, 04401
Contact: Thomas H. Openshaw    207-973-4274      
Principal Investigator: Thomas H. Openshaw         
United States, Maryland
Union Hospital of Cecil County Terminated
Elkton MD, Maryland, United States, 21921
United States, Michigan
West Michigan Cancer Center Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Raymond S. Lord    269-373-7458      
Principal Investigator: Raymond S. Lord         
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Geoffrey L. Uy    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Geoffrey L. Uy         
United States, Nebraska
University of Nebraska Medical Center Active, not recruiting
Omaha, Nebraska, United States, 68198
United States, New Hampshire
Dartmouth Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Christopher H. Lowrey    800-639-6918    cancer.research.nurse@dartmouth.edu   
Principal Investigator: Christopher H. Lowrey         
United States, New Jersey
Cooper Hospital University Medical Center Active, not recruiting
Camden, New Jersey, United States, 08103
United States, New Mexico
University of New Mexico Recruiting
Albuquerque, New Mexico, United States, 87106
Contact: Cecilia Y. Arana Yi    505-272-6972      
Principal Investigator: Cecilia Y. Arana Yi         
United States, New York
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: Meir Wetzler    877-275-7724      
Principal Investigator: Meir Wetzler         
North Shore University Hospital Recruiting
Manhasset, New York, United States, 11030
Contact: Ruthee-Lu Bayer    516-562-3467      
Principal Investigator: Ruthee-Lu Bayer         
North Shore-LIJ Health System CCOP Active, not recruiting
Manhasset, New York, United States, 11030
Long Island Jewish Medical Center Recruiting
New Hyde Park, New York, United States, 11040
Contact: Ruthee-Lu Bayer    516-562-3467      
Principal Investigator: Ruthee-Lu Bayer         
North Shore-LIJ Health System/Center for Advanced Medicine Recruiting
New Hyde Park, New York, United States, 11040
Contact: Ruthee-Lu Bayer    516-562-3467      
Principal Investigator: Ruthee-Lu Bayer         
Weill Medical College of Cornell University Active, not recruiting
New York, New York, United States, 10065
University of Rochester Recruiting
Rochester, New York, United States, 14642
Contact: Jonathan W. Friedberg    585-275-5830      
Principal Investigator: Jonathan W. Friedberg         
United States, North Carolina
Wake Forest University Health Sciences Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Bayard L. Powell    336-713-6771      
Principal Investigator: Bayard L. Powell         
United States, Ohio
The Jewish Hospital Recruiting
Cincinnati, Ohio, United States, 45236
Contact: James H. Essell    513-585-2859      
Principal Investigator: James H. Essell         
United States, Pennsylvania
Penn State Milton S Hershey Medical Center Recruiting
Hershey, Pennsylvania, United States, 17033-0850
Contact: David F. Claxton    717-531-3779    CTO@hmc.psu.edu   
Principal Investigator: David F. Claxton         
United States, Vermont
University of Vermont Recruiting
Burlington, Vermont, United States, 05401
Contact: Gurpreet Lamba    718-818-2952      
Principal Investigator: Gurpreet Lamba         
United States, Wisconsin
Gundersen Lutheran Recruiting
La Crosse, Wisconsin, United States, 54601
Contact: Kurt Oettel    608-775-2385    cancerctr@gundluth.org   
Principal Investigator: Kurt Oettel         
Sponsors and Collaborators
Investigators
Principal Investigator: Meir Wetzler Cancer and Leukemia Group B
  More Information

No publications provided

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01256398     History of Changes
Other Study ID Numbers: NCI-2011-02621, NCI-2011-02621, CDR0000690286, CALGB-10701, CALGB 10701/CTSU C10701, CALGB 10701/CTSU C10701, CALGB-10701, U10CA031946, P30CA014236
Study First Received: December 7, 2010
Last Updated: July 9, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Philadelphia Chromosome
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Translocation, Genetic
Chromosome Aberrations
Pathologic Processes
6-Mercaptopurine
Cytarabine
Methotrexate
Fludarabine monophosphate
Vidarabine
Cyclophosphamide
Melphalan
Tacrolimus
Campath 1G
Etoposide phosphate
Fludarabine
Alemtuzumab
Daunorubicin
Dexamethasone
Etoposide
Vincristine
BB 1101

ClinicalTrials.gov processed this record on July 22, 2014